Active substance
Ziprasidone
- US FDA 15
- Health Canada 8
- US price lines 6
- Safety 6
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| GEODON | EQ 20MG BASE; EQ 40MG BASE; EQ 60MG BASE; EQ 80MG BASE | capsule · oral | VIATRIS | Prescription | 5 Feb 2001 |
| GEODON | EQ 20MG BASE/VIAL | powder · intramuscular | VIATRIS | Prescription | 21 Jun 2002 |
| ZIPRASIDONE HYDROCHLORIDE | EQ 20MG BASE; EQ 40MG BASE; EQ 60MG BASE; EQ 80MG BASE | capsule · oral | APOTEX | Prescription | 2 Mar 2012 |
| ZIPRASIDONE HYDROCHLORIDE | EQ 20MG BASE; EQ 40MG BASE; EQ 60MG BASE; EQ 80MG BASE | capsule · oral | DR REDDYS LABS INC | Prescription | 2 Mar 2012 |
| ZIPRASIDONE HYDROCHLORIDE | EQ 20MG BASE; EQ 40MG BASE; EQ 60MG BASE; EQ 80MG BASE | capsule · oral | SANDOZ INC | Prescription | 1 Jun 2012 |
| ZIPRASIDONE HYDROCHLORIDE | EQ 20MG BASE; EQ 40MG BASE; EQ 60MG BASE; EQ 80MG BASE | capsule · oral | CHARTWELL RX | Prescription | 5 Sep 2012 |
| ZIPRASIDONE HYDROCHLORIDE | EQ 20MG BASE; EQ 40MG BASE; EQ 60MG BASE; EQ 80MG BASE | capsule · oral | AUROBINDO PHARMA | Prescription | 27 Dec 2016 |
| ZIPRASIDONE HYDROCHLORIDE | EQ 20MG BASE; EQ 40MG BASE; EQ 60MG BASE; EQ 80MG BASE | capsule · oral | MACLEODS PHARMS | Prescription | 17 Feb 2017 |
| ZIPRASIDONE HYDROCHLORIDE | EQ 20MG BASE; EQ 40MG BASE; EQ 60MG BASE; EQ 80MG BASE | capsule · oral | ZYDUS LIFESCIENCES | Prescription | 22 Aug 2017 |
| ZIPRASIDONE MESYLATE | EQ 20MG BASE/VIAL | powder · intramuscular | GLAND | Prescription | 26 Dec 2019 |
| ZIPRASIDONE MESYLATE | EQ 20MG BASE/VIAL | powder · intramuscular | MSN | Prescription | 15 Sep 2022 |
| ZIPRASIDONE MESYLATE | EQ 20MG BASE/VIAL | powder · intramuscular | STERISCIENCE | Prescription | 3 Sep 2025 |
| GEODON | EQ 10MG BASE/ML | suspension · oral | PFIZER INC | Discontinued | 29 Mar 2006 |
| ZIPRASIDONE HYDROCHLORIDE | EQ 20MG BASE; EQ 40MG BASE; EQ 60MG BASE; EQ 80MG BASE | capsule · oral | LUPIN PHARMS | Discontinued | 2 Mar 2012 |
| ZIPRASIDONE HYDROCHLORIDE | EQ 20MG BASE; EQ 40MG BASE; EQ 60MG BASE; EQ 80MG BASE | capsule · oral | MYLAN | Discontinued | 10 Oct 2013 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AURO-ZIPRASIDONE | 02449544 | 20 MG | CAPSULE · ORAL | AURO PHARMA INC |
| AURO-ZIPRASIDONE | 02449552 | 40 MG | CAPSULE · ORAL | AURO PHARMA INC |
| AURO-ZIPRASIDONE | 02449560 | 60 MG | CAPSULE · ORAL | AURO PHARMA INC |
| AURO-ZIPRASIDONE | 02449579 | 80 MG | CAPSULE · ORAL | AURO PHARMA INC |
| ZELDOX | 02298597 | 20 MG | CAPSULE · ORAL | BGP PHARMA ULC |
| ZELDOX | 02298600 | 40 MG | CAPSULE · ORAL | BGP PHARMA ULC |
| ZELDOX | 02298619 | 60 MG | CAPSULE · ORAL | BGP PHARMA ULC |
| ZELDOX | 02298627 | 80 MG | CAPSULE · ORAL | BGP PHARMA ULC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | GEODON 80 MG CAPSULE | $31.10811 | per EA | 3 Jun 2026 |
| US NADAC | ZIPRASIDONE 20 MG/ML VIAL | $21.8074 | per EA | 22 Jul 2026 |
| US NADAC | ZIPRASIDONE HCL 20 MG CAPSULE | $0.2694 | per EA | 23 Sep 2026 |
| US NADAC | ZIPRASIDONE HCL 40 MG CAPSULE | $0.27223 | per EA | 23 Sep 2026 |
| US NADAC | ZIPRASIDONE HCL 60 MG CAPSULE | $0.31396 | per EA | 23 Sep 2026 |
| US NADAC | ZIPRASIDONE HCL 80 MG CAPSULE | $0.31567 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 22 Jan 2025 GEODON — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Jan 2025 GEODON — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 23 Feb 2017 GEODON — safety-related labeling change
Labeling sections changed: Warnings and Precautions - EMA PRAC 11 Jun 2015 PRAC signal: Acute renal failure
Action for MAH: update of the product information: No - EMA PRAC 10 Apr 2015 PRAC signal: Drug reaction with eosinophilia and systemic symptoms (DRESS)
Action for MAH: update of the product information: No - EMA PRAC 6 Nov 2014 PRAC signal: Acute renal failure
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.